October 24, 2024

Overall Survival Analysis Confirms Pembrolizumab Regimen as Standard of Care for Triple-Negative Breast Cancer

For women with early-stage triple-negative breast cancer, KEYNOTE-522 changed the treatment paradigm several years ago. Support for neoadjuvant use of the PD-1 inhibitor pembrolizumab plus chemotherap...

The ASCO Post

October 31, 2024

PEACE-3: Enzalutamide Plus Radium-223 Significantly Improves Survival in Metastatic Castration-Resistant Prostate Cancer

The ASCO Post

October 24, 2024

NO-CUT Trial: Nonoperative Management of Benefit for Many Patients With Rectal Cancer

The ASCO Post

October 24, 2024

KEYNOTE-811: Pembrolizumab Combination in First-Line Setting Improves Overall Survival in Gastric Cancer

The ASCO Post

October 24, 2024

ADRIATIC Trial: Durvalumab Consolidation Extends Survival in Limited-Stage Small Cell Lung Cancer

The ASCO Post

October 09, 2024

HIMALAYA: 5-Year Analysis Confirms Survival Benefit of STRIDE Regimen in Hepatocellular Carcinoma

The ASCO Post

Latest Headlines

November 19, 2024

What Is the Impact of a Colon or Colorectal Cancer Diagnosis on Younger Adults vs Older Adults?

The ASCO Post

November 15, 2024

Detecting Evidence of Lung Cancer in Exhaled Breath

The ASCO Post

November 14, 2024

From Gaps to Bridges: Cancer Care Rooted in Equity, Quality, and Value

The ASCO Post

November 12, 2024

SITC: Study Finds IO102-IO103 Vaccine Plus Pembrolizumab Active in Patients With Non–Small Cell Lung Cancer

The ASCO Post

November 11, 2024

Neoadjuvant Therapy Yields Notable Outcomes in Triple-Negative Breast Cancer

The ASCO Post

November 08, 2024

Physician Wellness and Professional Burnout

The ASCO Post

Daily News

Stay up to date with the latest clinical headlines and other information tailored to your specialty.

Conference Coverage

All Conference News View Conference Calendar

2024 World Cancer Congress

November 14, 2024

From Gaps to Bridges: Cancer Care Rooted in Equity, Quality, and Value

The ASCO Post

October 09, 2024

Study Finds Nearly $70 Billion in Socioeconomic Losses Across 11 Countries Attributable to Ovarian Cancer

The ASCO Post

September 17, 2024

Study Finds Nearly $70 Billion in Socioeconomic Losses Across 11 Countries Attributable to Ovarian Cancer

The ASCO Post

2024 SITC Annual Meeting

November 12, 2024

SITC: Study Finds IO102-IO103 Vaccine Plus Pembrolizumab Active in Patients With Non–Small Cell Lung Cancer

The ASCO Post

NCCN Oncology Policy Summit

November 08, 2024

Advancing Diversity, Equity, and Inclusion Through a Challenging Policy Landscape

The ASCO Post

October 09, 2024

Creating a Culture of Diversity, Equity, and Inclusion: Why It Matters Clinically and Ethically

The ASCO Post

October 17, 2024

Advancing Diversity, Equity, and Inclusion Through a Challenging Policy Landscape

The ASCO Post

Clinical Guidelines

November 08, 2024

NCCN Guidelines Have Expanded to Meet Growing Understanding of Hereditary Risk

The ASCO Post

November 05, 2024

$2.5 Million Grant May Help Increase Lung Cancer Screenings in Underserved Communities

The ASCO Post

November 01, 2024

How End-of-Life Dreams and Visions Are Bringing Comfort to Dying Patients

The ASCO Post

July 01, 2023

GA THERAPIES ON THE WAY

Ophthalmology Management

Commentary & Perspectives

July 10, 2023

Expert Point of View: Pamela L. Kunz, MD and Corrie Marijnen, MD, PhD

The ASCO Post

January 25, 2023

Communicating Prognosis: A Core Competency of Patient-Centered Oncology Care

The ASCO Post

June 09, 2023

Rethinking Prior Authorization

The ASCO Post

October 25, 2023

Gender Equity in Academic Hematology: Where There’s a ‘WiL,’ There’s a Way

The ASCO Post

FDA & Government News

November 08, 2024

Tumor Treating Fields Therapy Receives FDA Approval in Metastatic NSCLC

The ASCO Post

November 08, 2024

FDA Approves Novel Combination for Gastric or Gastroesophageal Junction Adenocarcinoma

The ASCO Post

November 07, 2024

FDA Grants Accelerated Approval to Asciminib for Newly Diagnosed Chronic Myeloid Leukemia

The ASCO Post

July 18, 2023

First Oral Medication to Treat Moderate-to-Severe Crohn’s Disease Earns FDA Approval

Mount Sinai New York

Business Management

April 01, 2023

Change is Constant

Inside Dental Hygiene

February 08, 2023

Machine Learning and the Power to Outsmart Cancer

Cedars-Sinai Pulse

June 10, 2024

How the Museum of Medicine and Biomedical Discovery Aims to Bring Scientific Achievements of the Past, Present, and Future to Life

The ASCO Post

March 01, 2023

Exceeding Patient Expectations With Bioceramic Cements and More

Inside Dentistry

Trending Now

Trending Now

Find topic & conditions by first letter

Compendium

Inside Dental Hygiene

Inside Dental Technology

Inside Dentistry

Special Issues

The ASCO Post

JADPRO

JNCCN

JNCCN 360

Corneal Physician

Glaucoma Physician

New Retinal Physician

Ophthalmology Management

Ophthalmic Professional

Presbyopia Physician

Retinal Physician

Contact Lens Spectrum

Eyecare Business

Optometric Management

Presbyopia Physician

KEYNOTE-811: Pembrolizumab Combination in First-Line Setting Improves Overall Survival in Gastric Cancer

ADRIATIC Trial: Durvalumab Consolidation Extends Survival in Limited-Stage Small Cell Lung Cancer

HIMALAYA: 5-Year Analysis Confirms Survival Benefit of STRIDE Regimen in Hepatocellular Carcinoma

Latest Headlines

Daily News

Recommendations

Featured Videos

Conference Coverage

2024 World Cancer Congress

2024 SITC Annual Meeting

NCCN Oncology Policy Summit

Clinical Guidelines

Commentary & Perspectives

FDA & Government News

Business Management